Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla's stock experienced a decline in today's session, with the price decreasing by 1.45% to Rs 1498.10. There was high ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

Cipla, India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore.

In addition, Jefferies expects Tata Motors to see a tough year ahead with the demand for Indian trucks growing soft and the ...